<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05101616</url>
  </required_header>
  <id_info>
    <org_study_id>Camrelizumab-GC-neoadjuvant</org_study_id>
    <nct_id>NCT05101616</nct_id>
  </id_info>
  <brief_title>A Pilot Study of Neoadjuvant Chemotherapy With or Without Camrelizumab for Locally Advanced Gastric Cancer</brief_title>
  <official_title>A Pilot Study of Neoadjuvant Chemotherapy With or Without Camrelizumab for Locally Advanced Gastric Cancer: a Single-center, Open-label, Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Minimally Invasive Surgery Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Minimally Invasive Surgery Center</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      It is a single-center, open-lable, randomized controlled trial to prospectively investigate&#xD;
      the effectiveness and safety of Camrelizumab combined with DOS regimen chemotherapy in&#xD;
      neoadjuvant treatment of patients with locally advanced gastric cancer.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 1, 2022</start_date>
  <completion_date type="Anticipated">January 1, 2027</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2025</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>major pathologic response rate</measure>
    <time_frame>one month after surgery</time_frame>
    <description>complete or subtotal regression (&lt;10% residual tumor per tumor bed)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>complete pathologic response rate</measure>
    <time_frame>one month after surgery</time_frame>
    <description>complete regression (no residual tumor per tumor bed)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>R0 resection rate</measure>
    <time_frame>one month after surgery</time_frame>
    <description>surgically removed tissue without residual cancer cells</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>3 years</time_frame>
    <description>the time from the start of randomization to death due to any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-free survival</measure>
    <time_frame>3 years</time_frame>
    <description>the time from the start of randomization to the incurable resection, local recurrence or metastasis, or death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>perioperative complications</measure>
    <time_frame>the time from the start of randomization to 3 months after surgery</time_frame>
    <description>perioperative complications</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Gastric Cancer</condition>
  <arm_group>
    <arm_group_label>camrelizumab+chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>neoadjuvant treatment with camrelizumab+chemotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>chemotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>neoadjuvant treatment with chemotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>camrelizumab+chemotherapy</intervention_name>
    <description>camrelizumab 200mg，ivdrip，q3w； albumin nanoparticle of paclitaxel 260 mg/m2、 ivdrip，d1，q3w； oxaliplatine 85mg/m2、ivdrip，d1，q3w； S-1 40 mg/m2，po, bid，d1~d14，q3w. 3 cycles.</description>
    <arm_group_label>camrelizumab+chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chemotherapy</intervention_name>
    <description>albumin nanoparticle of paclitaxel 260 mg/m2、 ivdrip，d1，q3w； oxaliplatine 85mg/m2、ivdrip，d1，q3w； S-1 40 mg/m2，po, bid，d1~d14，q3w. 3 cycles.</description>
    <arm_group_label>chemotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subjects voluntarily join the study and sign an informed consent form, have good&#xD;
             compliance and cooperate with follow-up;&#xD;
&#xD;
          2. Male or female patients between the ages of 18-75;&#xD;
&#xD;
          3. Patients diagnosed as gastric adenocarcinoma by histology or cytology;&#xD;
&#xD;
          4. Stage: Locally advanced stage (T3-4aN1-3M0);&#xD;
&#xD;
          5. Have not received other immunotherapy drugs or chemotherapy drugs in the past;&#xD;
&#xD;
          6. ECOG (Eastern US Cooperative Oncology Group) score: 0-1 points;&#xD;
&#xD;
          7. Has sufficient organ and bone marrow function&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Other malignant tumors that have appeared or are currently suffering from within 5&#xD;
             years, except for cured cervical carcinoma in situ, non-melanoma skin cancer and&#xD;
             superficial bladder tumors [Ta (non-invasive tumor), Tis (carcinoma in situ) ) And T1&#xD;
             (tumor infiltration basement membrane)];&#xD;
&#xD;
          2. A distant metastasis occurs;&#xD;
&#xD;
          3. Those who have multiple factors that affect oral medications (such as inability to&#xD;
             swallow, chronic diarrhea, etc.);&#xD;
&#xD;
          4. Accompanied by pleural effusion or ascites, causing respiratory syndrome (NCI-CTC AE&#xD;
             V5.0 grade ≥ 2 dyspnea);&#xD;
&#xD;
          5. Patients with any severe and/or uncontrollable disease；&#xD;
&#xD;
          6. Patients with gastrointestinal diseases with bleeding tendency (such as active&#xD;
             gastrointestinal ulcers) or patients determined by the researcher to cause&#xD;
             gastrointestinal bleeding, perforation or obstruction&#xD;
&#xD;
          7. Patients whose imaging shows that the tumor has invaded the tissues around important&#xD;
             blood vessels or the investigator judges that the tumor is likely to invade important&#xD;
             blood vessels and cause fatal bleeding during the follow-up study;&#xD;
&#xD;
          8. Received glucocorticosteroid or immunosuppressive therapy within 7 days before&#xD;
             grouping;&#xD;
&#xD;
          9. Regardless of the severity, patients with any signs of bleeding or medical history;&#xD;
             within 4 weeks before grouping, patients with any bleeding or bleeding events NCI-CTC&#xD;
             AE V5.0 grade ≥ 3, unhealed wounds, ulcers Or fracture&#xD;
&#xD;
         10. Those who have had arterial/venous thrombotic events within 6 months, such as&#xD;
             cerebrovascular accidents (including temporary ischemic attacks), deep vein thrombosis&#xD;
             and pulmonary embolism;&#xD;
&#xD;
         11. People with a history of psychotropic drug abuse and unable to quit or have mental&#xD;
             disorders;&#xD;
&#xD;
         12. Participated in other anti-tumor drug clinical trials within four weeks;&#xD;
&#xD;
         13. According to the judgment of the investigator, those with concomitant diseases that&#xD;
             seriously endanger the safety of the patient or affect the completion of the study;&#xD;
&#xD;
         14. Female patients who are pregnant or breastfeeding;&#xD;
&#xD;
         15. Known hypersensitivity to any study drug.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 28, 2021</study_first_submitted>
  <study_first_submitted_qc>October 28, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 1, 2021</study_first_posted>
  <last_update_submitted>October 28, 2021</last_update_submitted>
  <last_update_submitted_qc>October 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>gastric cancer</keyword>
  <keyword>neoadjuvant chemotherapy</keyword>
  <keyword>immunotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

